StreetAlpha.app
Home › Stocks › SPRY

ARS Pharmaceuticals, Inc. (SPRY)

Healthcare
$2.96
▼ −11.90%
LAST CLOSE · NOV 20

ARS Pharma develops and sells neffy, a nasal spray form of epinephrine for emergency treatment of severe allergic reactions. It last closed at $2.96 on Nov 20, down 11.90% on the day. The next earnings report for SPRY is expected around Mon, Mar 8, 2027. For the quarter ended Sep 2026, SPRY reported EPS of -$0.36 on revenue of $37.7M, with revenue up 16.0% from a year ago. Over its last 8 reports the stock moved an average of 7.1% the session after earnings. Over the last 12 months SPRY insiders bought $0 of stock on the open market and sold $284K, according to SEC Form 4 filings.

AI Auto Pilots
Is SPRY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SPRY.

Key Stats

Last 12 months
Results
Revenue
$122.1M
−14.5% vs a year ago
Net income
−$199.9M
−163.6% margin
EPS (diluted)
−$2.01
Free cash flow
−$183.1M
−149.9% margin
Valuation
Market cap
$297.6M
100.5M shares
P/E
–
No P/E while losing money
Price to sales
2.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$25.6M
At Sep 30
Debt
$121.8M
At Sep 30
Shareholder equity
−$12.0M
Shares outstanding
100.5M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $5.5M$5.5MFY2021FY2022: $1.3M$1.3MFY2022FY2023: $30K$30KFY2023FY2024: $89.1M$89.1MFY2024FY2025: $84.3M$84.3MFY2025

From SPRY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · Time not announced
Reported EPS
-$0.36
Quarter ended Sep 2026
Year ago EPS
-$0.52
Same quarter last year
Revenue
$37.7M
+16.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.51Dec '24Mar 2025: -$0.35Mar '25Jun 2025: -$0.46Jun '25Sep 2025: -$0.52Sep '25Dec 2025: -$0.42Dec '25Mar 2026: -$0.61Mar '26Jun 2026: -$0.63Jun '26Sep 2026: -$0.36Sep '26Latest -$0.36
Revenue by quarter
Dec 2024: $86.6MDec '24Mar 2025: $8.0MMar '25Jun 2025: $15.7MJun '25Sep 2025: $32.5MSep '25Dec 2025: $28.1MDec '25Mar 2026: $22.7MMar '26Jun 2026: $33.7MJun '26Sep 2026: $37.7MSep '26Latest $37.7M
How SPRY moved after its last 8 reports
Average move the session after a report ±7.1%
Nov 5, 2026After the close+5.3%
Aug 13, 2026After the close−7.4%
May 15, 2026Time not announced−6.5%
Mar 9, 2026Time not announced−0.1%
Nov 10, 2025Time not announced+0.3%
Aug 13, 2025Time not announced−5.0%
May 14, 2025Time not announced−9.4%
Mar 20, 2025Time not announced+22.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SPRYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SPRY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SPRY

Technical Analysis

SPRY · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 16% below its 20 day and 32% below its 50 day average. It is 132% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $2.72, and the nearest resistance the Pivot at $3.09.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 13.2%/day
Key levels
$13.1552 week high+344.3%
$6.87200 day average+132.1%
$5.06100 day average+70.9%
$4.13Swing high (Nov 11)+39.5%
$3.9050 day average+31.8%
$3.4320 day average+15.9%
$3.33Pivot R1+12.5%
$3.09Pivot+4.4%
$2.96Last close
$2.72Pivot S1−8.1%
$2.4452 week low−17.6%
$2.44Swing low (Nov 6)−17.6%
Indicators
RSI (14)36.99Weak, oversold below 30Neutral
MACD-0.17Above its signal lineBullish
Stochastic53.1Middle of its rangeNeutral
ADX (14)21.7Weak trend
Williams %R-69.2Oversold below −80, overbought above −20Neutral
CCI (20)-70.0Oversold below −100, overbought above 100Neutral
Rate of change+6.1%Change over 10 sessionsBullish
ATR (14)$0.39Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRY

What happened before

See how SPRY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SPRY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SPRY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SPRYHow many large options trades hit SPRY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SPRY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●91 buying vs 100 selling
  • ▼Held by funds -2.0 pts
  • ▼Funds holding -16
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding191207−7.7%
In funds' top 1004−100.0%
Held by funds88.2%90.2%−2.0 pts
New / increased28 / 6337 / 73−17.3%
Reduced / sold out57 / 4356 / 31+14.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SPRY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SPRY Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$284K2 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
2026-06 sold $284KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 12Alexander A FitzpatrickChief Legal OfficerSale plan3,355$10.00$34K
Jun 12Eric KarasChief Commercial OfficerSale plan25,000$10.00$250K
Nov 13, 2025Brian DorseyCOOSale21,828$8.71$190K
Nov 12, 2025Justin ChakmaChief Business OfficerSale166,380$8.87$1.5M
Aug 21, 2025Kathleen D. ScottCFOSale plan12,500$15.00$188K
Aug 21, 2025Richard E LowenthalPresident And CEOSale plan50,000$14.49$725K
Every insider buy and sale for SPRY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SPRY insider trades →

From SEC Form 4 filings by SPRY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRY is in one of them and how their past SPRY trades turned out.

SPRY in the AI portfolios
Loading…

SPRY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SPRY in an article yet. Here's the latest on the wider market.

SPRY in the news

About ARS Pharmaceuticals

ARS Pharma is a biopharmaceutical company that develops and sells neffy, an epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis. The product is given through the nose without a needle, and it is sold under other trade names in Europe, the U.K. and China. Its customers include patients, caregivers, and the doctors who prescribe it, and partners help commercialize the product in several countries. The company is headquartered in San Diego, California.

Headquarters
San Diego, CA
Founded
2016